Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anesthetic Strategy, Functional Outcomes, and Infectious Complications After Mechanical Thrombectomy for Acute Ischemic Stroke.

Journal of clinical medicine·2026
Same author

The Effect of a Single Bout of Exercise to Volitional Exhaustion Under Moderate Normobaric Hypoxia on the Kinetics of Cardiac Biomarkers in Trained and Untrained Men.

International journal of molecular sciences·2026
Same author

Early treatment with ofatumumab increases the likelihood of stabilizing disease in patients with relapsing-remitting multiple sclerosis.

Archives of medical science : AMS·2026
Same author

Real-world effectiveness of onabotulinumtoxinA as first-line treatment in chronic migraine and sequential transition to anti-CGRP monoclonal antibodies: a retrospective multicenter study.

BMC neurology·2026
Same author

Cerebrolysin after Endovascular Thrombectomy in Stroke: 12‑Month Functional Outcomes in a Propensity‑Matched Cohort.

Translational stroke research·2026
Same author

Contrast-Associated Acute Kidney Injury After Thrombectomy for Ischemic Stroke: Prognostic Impact and CAN-REST Predictive Score.

Neurology·2026

Related Experiment Video

Updated: May 11, 2026

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

[Current state of research on multiple sclerosis].

Natalia Lubina-Dabrowska, Adam Stepień, Małgorzata Chalimoniuk

    Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego
    |May 25, 2013
    PubMed
    Summary

    Multiple sclerosis (MS) is a chronic autoimmune CNS disease affecting 2.5 million globally. While new treatments like fingolimod offer improved efficacy, they carry higher risks than older therapies.

    Area of Science:

    • Neuroimmunology
    • Neurology

    Background:

    • Multiple sclerosis (MS) is a chronic, autoimmune central nervous system (CNS) disease characterized by demyelination and irreversible disability.
    • Affecting approximately 2.5 million people worldwide, the exact pathomechanism of MS remains incompletely understood.
    • Current treatment options, including interferon-beta (IFN-beta) and glatiramer acetate (GA), offer limited efficacy in halting disease progression.

    Discussion:

    • Fingolimod and natalizumab represent advanced immunomodulatory therapies demonstrating greater effectiveness in managing MS compared to first-generation treatments.
    • However, these newer disease-modifying therapies are associated with an increased risk of adverse events.
    • The development of novel therapeutic strategies is crucial for addressing the unmet needs in MS management.

    Key Insights:

    More Related Videos

    Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
    09:41

    Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

    Published on: July 19, 2019

    Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis
    05:44

    Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis

    Published on: October 13, 2023

    Related Experiment Videos

    Last Updated: May 11, 2026

    Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
    08:51

    Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

    Published on: February 19, 2021

    Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
    09:41

    Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

    Published on: July 19, 2019

    Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis
    05:44

    Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis

    Published on: October 13, 2023

    • Newer MS drugs like fingolimod and natalizumab show enhanced efficacy over IFN-beta and GA.
    • These advanced treatments are linked to a higher incidence of side effects.
    • Understanding MS pathogenesis is key to developing safer and more effective therapies.

    Outlook:

    • Continued research into MS pathogenesis promises a deeper understanding of the disease.
    • The development of more effective and safer treatments for multiple sclerosis is anticipated.
    • Future therapeutic approaches aim to mitigate disability and improve patient outcomes in MS.